4.6 • 1.5K Ratings
🗓️ 11 November 2025
⏱️ 8 minutes
🧾️ Download transcript
Click on a timestamp to play from that location
| 0:00.0 | What would change for you if prescription prices were cut in half, and you could buy medications directly from the manufacturer? |
| 0:07.0 | Welcome to Dr. Mercola's Cellular Wisdom. |
| 0:10.0 | Stay informed with quick, easy-to-listen summaries of our latest articles, perfect for when you're on the go. |
| 0:15.0 | No reading required. Subscribe for free at Mercola.com for the latest health insights. Hello and welcome to Dr. Mercola's cellular wisdom. I'm Ethan Foster. |
| 0:26.6 | Today we're looking at Trump RX, a government-run website slated for 2026 that promises |
| 0:32.6 | discounted direct from manufacturer access to prescription drugs, along with a broader plan to tie U.S. |
| 0:38.9 | prices to those in other wealthy nations. |
| 0:41.5 | I'm Alara Sky. You'll hear what Trump R.X is designed to do, why Pfizer signed on as the |
| 0:47.7 | first partner, how most favored nation pricing fits in, and where analysts see benefits and limits. We'll also outline practical |
| 0:56.3 | steps from the article on how you can reduce your reliance on prescriptions by restoring cellular |
| 1:01.5 | energy. Prescription drugs in the U.S. are expensive, about 2.78 times higher than in other |
| 1:08.3 | developed countries, and more than 3.22 times higher for |
| 1:12.4 | many brand name products. That gap forces hard choices for millions, locking you into a system |
| 1:18.6 | where access often depends on what you can afford, not what you need. |
| 1:23.0 | Trump RX is presented as a direct-to-consumer portal that bypasses insurers, pharmacy benefit managers, |
| 1:30.1 | and wholesalers. Pfizer is the first major partner, pledging many drugs at up to 50% off-list |
| 1:36.8 | and committing to match prices in other wealthy countries. The company also plans a $70 billion |
| 1:42.9 | expansion of U.S. manufacturing, aided by a three-year |
| 1:46.7 | exemption from certain import tariffs. The policy backbone is a May 11, 2025 executive order |
| 1:54.1 | that reinstates most favored nations, pricing, requiring drug makers to charge Americans |
| 1:59.3 | no more than the lowest adjusted international price in peer markets. |
| 2:02.6 | The order targets high-cost Medicare Part B drugs and revives a rule once projected to save $87.8 billion over seven years. |
... |
Transcript will be available on the free plan in 13 days. Upgrade to see the full transcript now.
Disclaimer: The podcast and artwork embedded on this page are from Briana Mercola, and are the property of its owner and not affiliated with or endorsed by Tapesearch.
Generated transcripts are the property of Briana Mercola and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.
Copyright © Tapesearch 2025.